E-StOIC: European Study of Opioid Induced Constipation

Sponsor
University of Dublin, Trinity College (Other)
Overall Status
Recruiting
CT.gov ID
NCT05149833
Collaborator
(none)
1,320
1
14.5
91.3

Study Details

Study Description

Brief Summary

Constipation is common (40-90%) in advanced cancer patients , and has a significant negative impact on quality of life. The aetiology of constipation is often multifactorial in advanced cancer patients. However, it is well recognised that opioid analgesics are a common cause of constipation in this group. The prevalence of opioid-induced constipation (OIC) is stated to be 40-70%, although a recent large study reported an even higher figure.

OIC has been reported to exceed pain in terms of distress caused, and studies have found that some patients choose to reduce or discontinue opioid medication in order to attempt to better control constipation. Moreover, OIC is associated with a variety of physical (gastrointestinal, systemic), psychological and social problems.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    This European study follows on from a United Kingdom study, and aims to confirm findings of the previous study in a larger, more heterogeneous sample: it also aims to explore additional strategies to manage OIC. Moreover, the study aims to identify differences in perception of normal bowel habit / constipation, and differences in OIC management in the different European countries. Previous studies suggest that there are cultural differences in people's beliefs about constipation / normal bowel function. The aim of the project is to investigate OIC in a real world / heterogenous group of European patients with cancer.

    Study Design

    Study Type:
    Observational [Patient Registry]
    Anticipated Enrollment :
    1320 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    An Observational Study of Diagnostic Criteria, Clinical Features and Management of Opioid Induced Constipation (OIC) in European Patients With Cancer Pain
    Actual Study Start Date :
    Sep 16, 2021
    Anticipated Primary Completion Date :
    Nov 30, 2022
    Anticipated Study Completion Date :
    Nov 30, 2022

    Outcome Measures

    Primary Outcome Measures

    1. Prevalence of opioid induced constipation (OIC) [5 minutes]

      OIC diagnosed using Rome IV diagnostic criteria

    Secondary Outcome Measures

    1. Impact of OIC on quality of life [5 minutes]

      Patient Assessment of Constipation Quality of Life tool score

    2. Efficacy of treatment for OIC [3 minutes]

      Bowel Function Index tool score

    3. Adherence with treatment for OIC [5 min]

      Study questionnaire

    4. Use of non-prescribed treatments for OIC [5 min]

      Study questionnaire

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Age 18 years or over

    • Diagnosis of cancer

    • Diagnosis of cancer pain or cancer treatment-related pain

    • Taking regular opioids for at least one week (i.e. opioid for mild to moderate pain / "weak" opioid; or opioid for moderate to severe pain / "strong" opioid)

    Exclusion Criteria:
    • Unable to provide consent

    • Unable to complete questionnaire

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Our Lady's Hospice & Care Services Dublin Ireland D6W EV82

    Sponsors and Collaborators

    • University of Dublin, Trinity College

    Investigators

    • Principal Investigator: Andrew Davies, MD, University of Dublin, Trinity College

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Prof Andrew Davies, Professor of Palliative Medicine, University of Dublin, Trinity College
    ClinicalTrials.gov Identifier:
    NCT05149833
    Other Study ID Numbers:
    • PM2021/65
    First Posted:
    Dec 8, 2021
    Last Update Posted:
    Dec 8, 2021
    Last Verified:
    Nov 1, 2021
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Dec 8, 2021